Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$57.25 +0.1%	$58.00	$52.93 ▼ $94.85	$10.98B	0.17	1.73 million shs	1.38 million shs
GNMSF Genmab A/S	$198.51 -3.2%	$208.07	$170.00 ▼ $292.80	$13.12B	0.91	37 shs	24 shs
GRFS Grifols	$9.08 -0.7%	$8.21	$6.19 ▼ $9.96	$6.24B	0.55	1.12 million shs	191,164 shs
MKGAF Merck KGaA	$134.76 +0.0%	$134.07	$118.05 ▼ $200.56	$17.42B	0.96	1,081 shs	163 shs
UCBJF UCB	$199.84 0.0%	$177.82	$149.85 ▼ $209.66	$37.77B	0.47	552 shs	2 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	+0.14%	+5.82%	+0.81%	-5.00%	-29.30%
GNMSF Genmab A/S	-3.17%	-5.96%	-6.37%	+6.64%	-19.09%
GRFS Grifols	-0.71%	+3.36%	+8.81%	+36.47%	+36.67%
MKGAF Merck KGaA	+0.04%	+4.87%	-0.95%	+7.42%	-18.33%
UCBJF UCB	-0.03%	+1.01%	+11.40%	+17.55%	+51.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMRN BioMarin Pharmaceutical	4.9442 of 5 stars	3.4	3.0	0.0	3.3	2.7	2.5	4.4
GNMSF Genmab A/S	0.8277 of 5 stars	0.0	3.0	0.0	0.0	2.2	0.0	1.3
GRFS Grifols	4.065 of 5 stars	2.5	5.0	0.0	0.0	1.6	0.0	5.0
MKGAF Merck KGaA	1.6307 of 5 stars	0.0	1.0	0.0	0.0	3.1	0.0	3.1
UCBJF UCB	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRN BioMarin Pharmaceutical	2.75	Moderate Buy	$93.61	63.51% Upside
GNMSF Genmab A/S	0.00	N/A	N/A	N/A
GRFS Grifols	3.00	Buy	$10.30	13.50% Upside
MKGAF Merck KGaA	4.00	Strong Buy	N/A	N/A
UCBJF UCB	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest GRFS, MKGAF, UCBJF, BMRN, and GNMSF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	BMRN BioMarin Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$97.00
6/23/2025	UCBJF UCB	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Overweight
6/17/2025	GRFS Grifols	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.60 ➝ $10.30
5/5/2025	BMRN BioMarin Pharmaceutical	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$124.00 ➝ $104.00
5/2/2025	BMRN BioMarin Pharmaceutical	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$82.00 ➝ $78.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRN BioMarin Pharmaceutical	$2.85B	3.85	$3.25 per share	17.61	$29.69 per share	1.93
GNMSF Genmab A/S	$3.12B	4.20	$14.70 per share	13.50	$80.53 per share	2.46
GRFS Grifols	$7.81B	0.80	$0.93 per share	9.76	$13.55 per share	0.67
MKGAF Merck KGaA	$22.72B	0.77	$40.59 per share	3.32	$212.00 per share	0.64
UCBJF UCB	$5.27B	7.17	$8.58 per share	23.28	$50.52 per share	3.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRN BioMarin Pharmaceutical	$426.86M	$2.69	21.28	13.13	0.78	17.76%	11.34%	8.95%	8/4/2025 (Estimated)
GNMSF Genmab A/S	$1.14B	$17.63	11.26	∞	N/A	35.11%	19.23%	15.44%	8/7/2025 (Estimated)
GRFS Grifols	$169.80M	$1.17	7.76	8.64	0.33	N/A	N/A	N/A	7/29/2025 (Estimated)
MKGAF Merck KGaA	$3.06B	$6.81	20.57	12.77	N/A	12.60%	10.17%	5.74%	8/7/2025 (Estimated)
UCBJF UCB	$371.23M	N/A	0.00	28.31	N/A	N/A	N/A	N/A	7/23/2025 (Estimated)

Latest GRFS, MKGAF, UCBJF, BMRN, and GNMSF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/29/2025	Q2 2025	GRFS Grifols	$0.2221	N/A	N/A	N/A	$1.92 billion	N/A
5/8/2025	Q1 2025	GNMSF Genmab A/S	$1.88	$3.05	+$1.17	$3.05	$761.09 million	$765.14 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
GNMSF Genmab A/S	N/A	N/A	N/A	N/A	N/A
GRFS Grifols	N/A	N/A	N/A	N/A	N/A
MKGAF Merck KGaA	N/A	N/A	N/A	N/A	N/A
UCBJF UCB	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRN BioMarin Pharmaceutical	0.10	5.52	3.49
GNMSF Genmab A/S	N/A	5.34	5.32
GRFS Grifols	1.13	2.60	0.97
MKGAF Merck KGaA	0.27	1.31	0.84
UCBJF UCB	0.33	1.19	0.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRN BioMarin Pharmaceutical	98.71%
GNMSF Genmab A/S	N/A
GRFS Grifols	N/A
MKGAF Merck KGaA	0.10%
UCBJF UCB	N/A

Insider Ownership

Company	Insider Ownership
BMRN BioMarin Pharmaceutical	0.85%
GNMSF Genmab A/S	1.54%
GRFS Grifols	0.19%
MKGAF Merck KGaA	N/A
UCBJF UCB	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRN BioMarin Pharmaceutical	3,040	191.78 million	190.15 million	Optionable
GNMSF Genmab A/S	2,682	66.07 million	65.06 million	Not Optionable
GRFS Grifols	23,822	687.55 million	686.25 million	Optionable
MKGAF Merck KGaA	62,908	129.24 million	N/A	Not Optionable
UCBJF UCB	9,083	189.02 million	N/A	Not Optionable

GRFS, MKGAF, UCBJF, BMRN, and GNMSF Headlines

Recent News About These Companies

UCB (OTCMKTS:UCBJF) Share Price Crosses Above Fifty Day Moving Average - Should You Sell?

July 4 at 6:46 AM | marketbeat.com

UCB (OTCMKTS:UCBJF) Shares Gap Down - Should You Sell?

June 30, 2025 | marketbeat.com

UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences

May 20, 2025 | finance.yahoo.com

United Community Banks, Inc. (UCB) Q1 2025 Earnings Call Transcript

April 22, 2025 | seekingalpha.com

UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025

April 3, 2025 | finance.yahoo.com

UCB Convening Notice to the General Meeting of the Shareholders 2025

March 21, 2025 | finance.yahoo.com

UCB price target raised to EUR 220 from EUR 130 at Berenberg

February 25, 2025 | markets.businessinsider.com

UCB price target raised to EUR 200 from EUR 105 at Morgan Stanley

February 12, 2025 | markets.businessinsider.com

UCB assumed with an Equal Weight at Morgan Stanley

February 12, 2025 | markets.businessinsider.com

UCB SA (0NZT) Receives a Hold from Kepler Capital

February 2, 2025 | markets.businessinsider.com

UCB SA (0NZT) Gets a Buy from Barclays

January 27, 2025 | markets.businessinsider.com

United Community Banks, Inc. (UCB) Q4 2024 Earnings Call Transcript

January 22, 2025 | seekingalpha.com

UCB SA (0NZT) Receives a Buy from Barclays

January 16, 2025 | markets.businessinsider.com

UCB price target raised to EUR 215 from EUR 200 at Deutsche Bank

November 12, 2024 | markets.businessinsider.com

UBS Remains a Buy on UCB SA (0NZT)

November 4, 2024 | markets.businessinsider.com

Artisan Global Equity Fund Q3 2024 Commentary

October 25, 2024 | seekingalpha.com

Artisan International Fund Q3 2024 Commentary

October 25, 2024 | seekingalpha.com

Bimzelx Powers UCB To New Heights: Deep Dive Into The Company's Growth Strategy

October 18, 2024 | seekingalpha.com

Barclays Keeps Their Buy Rating on UCB SA (0NZT)

October 7, 2024 | markets.businessinsider.com

UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

September 30, 2024 | finance.yahoo.com

UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

September 28, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRFS, MKGAF, UCBJF, BMRN, and GNMSF Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

$57.25 +0.08 (+0.14%)

Closing price 07/3/2025 03:45 PM Eastern

Extended Trading

$57.24 -0.01 (-0.01%)

As of 07/3/2025 04:58 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Genmab A/S OTCMKTS:GNMSF

$198.51 -6.49 (-3.17%)

As of 07/3/2025 12:46 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Grifols NASDAQ:GRFS

$9.07 -0.07 (-0.71%)

As of 07/3/2025 01:04 PM Eastern

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Merck KGaA OTCMKTS:MKGAF

$134.76 +0.05 (+0.04%)

As of 07/3/2025 11:56 AM Eastern

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

UCB OTCMKTS:UCBJF

$199.84 -0.05 (-0.03%)

As of 07/3/2025 12:48 PM Eastern

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time